Journal: Metabolism Open
Article Title: Hepatic activating transcription factor 3 protects against systemic inflammation by attenuating lipotoxicity
doi: 10.1016/j.metop.2025.100417
Figure Lengend Snippet: Hepatocytic ATF3 is required for protection against HF diet-induced hepatic lipotoxicity likely mediated through AMPKα activation. (A–F) C57BL/6J mice were injected with AAV8-TBG-Null or AAV8-TBG-hATF3 via the tail vein, then fed an HF diet for 16 weeks (n = 6 per group). Hepatic levels of triglyceride (A), total cholesterol (B) and free fat acid (C) were quantified. (D) Hepatic reactive oxygen species levels. (E) Oil red O staining of liver sections. (F) Hepatic protein levels were determined by Western blot assays and quantified. (G–L) Atf3 fl/fl and Atf3 Hep−/− mice were fed an HF diet for 20 weeks (n = 6 per group). Hepatic levels of triglyceride (G), total cholesterol (H) and free fat acid (I) were quantified. (J) Hepatic reactive oxygen species levels. (K) Oil red O staining of liver sections. (L) Hepatic protein levels were determined by Western blot assays and quantified. Scale bars in E and K: 50 μm. All values are expressed as mean ± SEM. ∗ P < 0.05, ∗∗ P < 0.01 vs. control. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Article Snippet: AAV8-TBG-Null (control), AAV8-TBG-Cre, and AAV8-TBG -hATF3 were produced and titrated by OBiO Technology Corp (Shanghai).
Techniques: Activation Assay, Injection, Staining, Western Blot, Control